This page shows the latest infectious diseases news and features for those working in and with pharma, biotech and healthcare.
of Allergy and Infectious Diseases (NIAID).
The results from phase 1 and phase 2 trials, published in The Lancet Infectious Diseases, evaluated the CoronaVac vaccine in over 700 participants.
potential infection due to viral exposure," said Lidia Oostvogels, head of infectious diseases of CureVac.
The phase 3 ENSEMBLE trial is being conducted in collaboration with the US Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).
Following the approval, the director of the US National Institute of Allergy and Infectious Diseases (NIAID) Dr Anthony Fauci initially commented that the UK’s approval process for the vaccine had
Anthony Fauci apologised for previous comments in BBC interview. The director of the US National Institute of Allergy and Infectious Diseases (NIAID) Dr Anthony Fauci (pictured above) has apologised after previously
More from news
Approximately 4 fully matching, plus 220 partially matching documents found.
There is no market for sporadic infectious diseases. Even the use of the word ‘market’ is incorrect. ... And we know how to translate academic inventions into medicines that can help patients, but today that’s not happening, because there is no
medicine. to contribute to the medical response in public health emergencies. The EUA was based on then available data from two global clinical trials – the National Institute for Allergy and Infectious ... Diseases’ (NIAID) placebo-controlled phase
I don’t think the ongoing trials will tell us a lot,” said H Clifford Lane, clinical director at the National Institutes of Allergy and Infectious Diseases (NIAID). ... IL-6 is a type of cytokine that plays an important role in immune response and is
It is, therefore, critical that action is taken to stop the re-emergence of dangerous infectious diseases.
He moved to the University of Rochester as Associate Professor for 5 years, before becoming Infectious Diseases Division Chief and tenured full Professor at the University of California, Davis. ... In 2005, he joined the Novartis Institutes for
More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.
In his new role, he will become a member of the firm’s senior management team, and will continue to oversee key client engagements in infectious diseases, vaccines and immuno-oncology.
Over her 15-year career, Peck has worked across a range of healthcare communications areas, including oncology, dermatology, infectious diseases and more.
Most recently, she held the position of vice president of M&A operations and divestitures and led the infectious diseases and vaccines business development. ... She joins Eisai from Merck, where she served as executive director, clinical quality assurance
and infectious diseases.
Commenting on the appointment, Dr Colin Broom, chief executive officer of Nabriva, said: “Jennifer has broad expertise in infectious diseases and internal medicine with extensive experience in both clinical development and
More from appointments
Approximately 0 fully matching, plus 38 partially matching documents found.
The Coalition for Epidemic Preparedness Innovation (CEPI), a global alliance financing and coordinating the development of vaccines against emerging infectious diseases, launched in 2017 and is needed now more than ever. ... These three factors all aid
Professor Jean Paul Stahl, Professor of Infectious Diseases, University Hospital, Grenoble, France. ... Former President of the French Infectious Diseases Society. Edmund Pezalla, Former Vice President, National Medical Director, Pharmaceutical Policy
Betty has worked on a wide variety of medical education initiatives in various therapeutic areas including immuno-oncology, infectious diseases, transplantation and multiple sclerosis. ... Katherine has a background in oncology, neurology, metabolic
In a globalised world, infectious diseases can travel long distances in relatively short periods of time, making the problem of resistance one that is relevant to all seven billion of us
Emily Macdonald calls on her experience as a public health nurse specialising in the prevention of infectious disease in both the US and UK, to explore the differences between immunisation programmes ... We understand infectious diseases so well that we
More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...